Story
FTAI Aviation Announces $500 Million Share Repurchase Program
Summary
The aviation company's board has authorized a new buyback program running through September 2029, sending shares up 3.7% in after-hours trading.
FTAI Aviation Ltd. (NASDAQ:FTAI) saw its shares climb in after-hours trading Tuesday after the company announced its board of directors has authorized a new share repurchase program of up to $500 million.
Program Details
The buyback program is set to run through September 30, 2029, and will be funded with cash on the company's balance sheet, according to the announcement. The authorization allows management to repurchase shares at its discretion through various methods.
These methods may include:
- Open market purchases at prevailing prices
- Privately negotiated transactions
- Block trades
- Other legally permissible means, including Rule 10b5-1 trading plans
AdThe program does not obligate FTAI to acquire a specific number of shares. The timing and volume of any repurchases will depend on the stock's price, overall market conditions, and legal requirements. The company also noted it can suspend, modify, or terminate the program at any time.
Market Reaction and Context
Following the news, shares of FTAI Aviation rose 3.7% in after-hours trading on Tuesday. Share buyback programs are often viewed by investors as a sign of management's confidence in the company's valuation and future prospects.
By reducing the number of outstanding shares, repurchases can also have an accretive effect on earnings per share (EPS), a key metric for shareholders. This action provides a potential mechanism for returning capital to investors, alongside dividends.
Read next
More on Stocks
BOJ Rate Hike Nears, Pitting Japanese Financials Against Exporters
The Bank of Japan is widely expected to raise its key interest rate to a 31-year high this week, a move that is creating a sharp divide in the stock market between beneficiaries like banks and sectors facing pressure, such as exporters.
Genscript Biotech Stock Surges Over 16% on Eli Lilly AI Partnership
Shares in the Hong Kong-listed biotech firm rallied after announcing a collaboration with Eli Lilly's AI-powered drug discovery platform, a move supported by a recent capital raise focused on AI infrastructure.
Volkswagen's Seat Brand Faces Discontinuation Amid Chinese EV Pressure
Volkswagen is reportedly set to phase out its historic Spanish brand, Seat, as part of a major restructuring to combat rising competition from Chinese automakers and focus investment on its profitable, all-electric Cupra marque.
Hong Kong Biotech Sector Shows Stark Divide as Biocytogen, Genscript Post Major Gains
A small group of companies, led by Biocytogen Pharmaceuticals and Genscript Biotech, have delivered substantial one-year returns, highlighting a sharp performance gap within Hong Kong's 52-stock biotech universe where most firms remain unprofitable.